D13.7
Benign neoplasm of endocrine pancreas
Clinical Classification Guidelines
Use Additional Code
- code to identify any functional activity.
Inclusion Terms
- Islet cell tumor
- Benign neoplasm of islets of Langerhans
Medical Intelligence & Overview
A benign neoplasm of the endocrine pancreas, often referred to as an islet cell tumor, is a non-cancerous growth that develops from the islets of Langerhans within the pancreas. These tumors are generally slow-growing and do not spread to other parts of the body. The pancreas is an essential organ that plays a vital role in digestion and hormone regulation, including insulin production. When a benign tumor forms in the endocrine part of the pancreas, it is classified under ICD-10 code D13.7. While benign, these tumors require medical evaluation and management to monitor any changes in size or function.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting cell growth within pancreatic islets Inherited syndromes such as Multiple Endocrine Neoplasia (MEN) types 1 and 4 Family history of pancreatic tumors Radioactive or chemical exposure Long-standing endocrine diseases affecting pancreatic function
Key Symptoms: Abdominal pain or discomfort Palpable abdominal mass Unexplained weight loss Nausea or vomiting Symptoms related to hormone excess, such as: Hypoglycemia (low blood sugar) if insulin-secreting tumors are present Wheezing or skin flushing if associated with carcinoid syndrome Symptoms related to hormone deficiency or overproduction
Diagnostic & Treatment
Diagnosis Path: Medical history review and physical examination Imaging tests such as computed tomography (CT) scan or magnetic resonance imaging (MRI) Endoscopic ultrasound to obtain detailed images and possibly a biopsy Laboratory tests measuring hormone levels, especially if hormone secretion symptoms are present Histopathological examination of tissue samples to confirm benign nature
Treatment Protocols: Regular monitoring with imaging and blood tests for tumors that are asymptomatic and small Surgical removal for symptomatic tumors or those increasing in size Less invasive procedures such as enucleation for accessible tumors Postoperative care and follow-up to detect any recurrence or complications Medical management to control hormone-related symptoms if active hormone secretion occurs
Clinical Advice & FAQs
Billing Guidance
Is D13.7 a billable ICD-10 code?
Yes, D13.7 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D13.7?
Clinical documentation must specify the nature of Benign neoplasm of endocrine pancreas and any associated comorbidities for accurate reporting.
Cite this Clinical Reference